Genetics and poor healthcare contribute to Black men's prostate cancer disparities. Unequal care, not biology, is the root ...

Guidelines created by a multi-disciplinary panel of specialists ... they called out the need for routine genetic testing of patients with advanced prostate cancer and emphatically called out ...

A review of 22 trials led the American Society of Clinical Oncology (ASCO) to issue updates to its mCRPC systemic therapy ...

A U.S. FDA panel of independent experts beat ... for individuals with castration-resistant prostate cancer that have the HRR gene mutation. Pfizer submitted an sNDA to have the drug used with ...

Researchers have identified a gene that plays a key role in prostate cancer cells that have transitioned to a more aggressive, treatment-resistant form. The gene can be indirectly targeted with an ...

New findings suggest that a PSA level of 0.2 ng/mL or greater can predict a poor prognosis and indicate a possible need for ...

In an 8-0 vote, members of the Oncologic Drugs Advisory Committee (ODAC) said the available data from the TALAPRO-2 trial do not support a favorable risk-benefit profile of talazoparib plus ...

Using a custom genotyping panel, polygenic risk scores were calculated based on 130 prostate cancer–associated single-nucleotide polymorphisms (SNPs). Those in the top 10% of genetic risk (≥ ...

A recent study from the Institute of Biomedicine at the University of Eastern Finland shows that the glucocorticoid receptor ...